Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03326323 · ClinicalTrials.gov registry record
Biomarker and Thrombogenicity Assessment in Cardiopulmonary Bypass Surgery Utilizing Acute Normovolemic Hemodilution
A clinical trial, sponsored by Inova Health Care Services.
- Completed
- Registry status
- 43
- Enrollment target
NCT03326323: Completed study, sponsored by Inova Health Care Services.
NCT03326323 is a clinical trial that has completed, run by Inova Health Care Services. The registered enrollment target is 43 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03326323 has completed, sponsored by Inova Health Care Services.
- COMPLETED
- Registry status
- 43 participants
- Enrollment target
Study Summary
This study will help enhance current understanding of the impact of Acute Normovolemic Hemodilution (ANH) administration on transfusion requirements post cardiac surgery, the effect of this procedure on coagulation, and platelet hemostasis, and the amount of chest tube drainage 24 hours post coronary artery bypass graft surgery (CABG) surgery.
Primary Outcome
Time it takes (hours) for platelet function to recover post-ANH to pre-procedure levels as measured by platelet aggregation.
Interventions
- PROCEDURE Acute Normovolemic Hemodilution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2018-03-19 |
| Est. Completion | 2019-10-17 |
What the finished NCT03326323 record still lists
NCT03326323 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 43 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Acute Normovolemic Hemodilution is the first listed.
NCT03326323 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03326323 about?
NCT03326323 is a clinical study titled "Biomarker and Thrombogenicity Assessment in Cardiopulmonary Bypass Surgery Utilizing Acute Normovolemic Hemodilution". This study will help enhance current understanding of the impact of Acute Normovolemic Hemodilution (ANH) administration on transfusion requirements post cardiac surgery, the effect of this procedure on coagulation, and platelet hemostasis, and the amount of chest tube drainage 24 hours post coronar...
What is the current status of trial NCT03326323?
This trial is currently completed. The enrollment target is 43 participants. The study started on 2018-03-19. Estimated completion is 2019-10-17.
What interventions are being tested in trial NCT03326323?
The interventions under investigation include: Acute Normovolemic Hemodilution (PROCEDURE).
Who is sponsoring clinical trial NCT03326323?
This trial is sponsored by Inova Health Care Services, which has 75 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03726359 · 43 participants · Phase 1
Phase I Study of Fractionated Stereotactic Radiation Therapy
- NCT03850418 · 43 participants · Phase 2
Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant
- NCT04144023 · 43 participants · Phase 1
A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ
- NCT04176718 · 43 participants · Phase 2
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI